2021
Dopamine D1R Receptor Stimulation as a Mechanistic Pro-cognitive Target for Schizophrenia
Abi-Dargham A, Javitch JA, Slifstein M, Anticevic A, Calkins ME, Cho YT, Fonteneau C, Gil R, Girgis R, Gur RE, Gur RC, Grinband J, Kantrowitz J, Kohler C, Krystal J, Murray J, Ranganathan M, Santamauro N, Van Snellenberg J, Tamayo Z, Wolf D, D’Souza D, Srihari V, Gueorguieva R, Patel P, Forselius-Bielen K, Lu J, Butler A, Fram G, Afriyie-Agyemang Y, Selloni A, Cadavid L, Gomez-Luna S, Gupta A, Radhakrishnan R, Rashid A, Aker R, Abrahim P, Nia A, Surti T, Kegeles L, Carlson M, Goldberg T, Gangwisch J, Benedict E, Govil P, Brazis S, Mayer M, de la Garrigue N, Fallon N, Baumvoll T, Abeykoon S, Perlman G, Bobchin K, Elliott M, Schmidt L, Rush S, Port A, Heffernan Z, Laney N, Kantor J, Hohing T, Gray D, Lieberman J. Dopamine D1R Receptor Stimulation as a Mechanistic Pro-cognitive Target for Schizophrenia. Schizophrenia Bulletin 2021, 48: 199-210. PMID: 34423843, PMCID: PMC8781338, DOI: 10.1093/schbul/sbab095.Peer-Reviewed Original ResearchConceptsCortical dopamine neurotransmissionPositive allosteric modulationImportant therapeutic targetPF-06412562Dopaminergic receptorsD1R stimulationDA levelsTolerable dosesLevel of stimulationDopamine neurotransmissionReceptor stimulationTherapeutic targetPartial agonistCognitive deficitsBiased agonismFull agonismTarget engagementAllosteric modulationNew drugsStimulationPoor bioavailabilitySchizophreniaOptimal stimulationDrugsExpression levels
2020
Cannabinoid use in psychotic patients impacts inflammatory levels and their association with psychosis severity
Gibson CL, Bassir Nia A, Spriggs SA, DeFrancisco D, Swift A, Perkel C, Zhong X, Mazumdar M, Fernandez N, Patel M, Kim-Schulze S, Hurd YL. Cannabinoid use in psychotic patients impacts inflammatory levels and their association with psychosis severity. Psychiatry Research 2020, 293: 113380. PMID: 32818918, PMCID: PMC8292796, DOI: 10.1016/j.psychres.2020.113380.Peer-Reviewed Original ResearchConceptsInterleukin-6Psychosis severityCannabinoid useCannabis useIL-6 levelsCommon underlying pathologyPANSS total scoreChronic psychotic disordersRisk of psychosisPsychiatric emergency roomNegative Syndrome ScalePsychotic symptom severityInflammatory alterationsInflammatory markersInflammatory disturbancesAcute psychosisInflammatory abnormalitiesNata medicationUnderlying pathologyEmergency roomInflammatory levelsPANSS scoresPsychiatric unitUnadjusted modelsPsychotic disorders
2019
The Relevance of Sex in the Association of Synthetic Cannabinoid Use With Psychosis and Agitation in an Inpatient Population.
Bassir Nia A, Mann CL, Spriggs S, DeFrancisco DR, Carbonaro S, Parvez L, Galynker II, Perkel CA, Hurd YL. The Relevance of Sex in the Association of Synthetic Cannabinoid Use With Psychosis and Agitation in an Inpatient Population. The Journal Of Clinical Psychiatry 2019, 80 PMID: 31265768, PMCID: PMC8445109, DOI: 10.4088/jcp.18m12539.Peer-Reviewed Original ResearchConceptsToxicology screenRelevance of sexSynthetic cannabinoid useSC usePositive urine toxicology screenCannabinoid useUrine toxicology screenRetrospective chart reviewPositive toxicology screenEffects of cannabinoidsSC usersRates of psychosisChart reviewPharmacologic treatmentClinical symptomsInpatient populationInpatient settingPsychotic presentationsUse of substancesStudy groupHigh riskPsychiatric unitCurrent evidenceControl groupPsychosis